OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
4,98Â US$
arrow_upward
+1,12%(+0,055) 1 d
16 okt., 16:00:00 GMT−4 · USD
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för OPHLY …
Öppen
5,05Â US$
Högt
5,07Â US$
LÃ¥gt
4,98Â US$
Börsvärde
1,20Â bn
Genomsn. vol.
62,80Â tn
Volym
20,91Â tn
52v högst
5,75Â US$
52v lägst
3,82Â US$
Beta
0,21
Utestående aktier
1,50Â md
Antal anställda
4Â tn
Öppen
5,05Â US$
Högt
5,07Â US$
LÃ¥gt
4,98Â US$
Börsvärde
1,20Â bn
Genomsn. vol.
62,80Â tn
Volym
20,91Â tn
52v högst
5,75Â US$
52v lägst
3,82Â US$
Beta
0,21
Utestående aktier
1,50Â md
Antal anställda
4Â tn
Nyheter och artiklar
Från webbkällor och nyhetspartner
Vietnam.vn
·
för 1 dag sedan
Snabbläsning 16-10: Dow Jones stiger över 550 poäng då obligationsräntorna faller, PV Power uppskattar 9-månaders vinst till över 5 400 miljarder VND
HurBra.se
·
för 20 timmar sedan
USA-börsen 15 oktober 2026: Vård lyfte, AI pressades
Law360
·
för 24 minuter sedan
Nasdaq Sued Over Delisting Of Social Media Co.
Simply Wall Street
·
för 15 minuter sedan
SK Hynix (NasdaqGS:SKHY) Stock Trades At A Discount After A 22% Fall
Profil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Om Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
VdGyo Sagara | Gyo Sagara
Anställda4,21 tn
Grundades1717
HuvudkontorOsaka, Osaka prefektur, Japan
Sektor-
Webbplatsono-pharma.com